alexa How Can we Improve Non-Surgical Septal Reduction for Hy
ISSN: 2329-9517

Journal of Cardiovascular Diseases & Diagnosis
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Short Communication

How Can we Improve Non-Surgical Septal Reduction for Hypertrophic Obstructive Cardiomyopathy?

John H Cleator1*, Ehab S Kasasbeh1, David X Zhao2 and Douglas B Sawyer3*

1Department of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA

2Wake Forest Baptist Medical Center, Wake Forest, USA

3Maine Medical Center, Portland, Oregon, USA

*Corresponding Author:
Cleator JH
Department of Cardiovascular Medicine Vanderbilt
University Medical Center, Nashville, Tennessee, USA
Tel: 6159361713
Fax: 6159361847
[email protected]

Received date: June 04, 2016 Accepted date: June 21, 2016; Published date: July 01, 2016

Citation: Cleator JH, Kasasbeh ES, Zhao DX, Sawyer DB (2016) How can we Improve Non-surgical Septal Reduction for Hypertrophic Obstructive Cardiomyopathy?. J Cardiovasc Dis Diagn 4:246. doi:10.4172/2329-9517.1000246

Copyright: © 2016 Cleator JH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



The goal for treatment of medical refractory Hypertrophic Obstructive Cardiomyopathy (HCM) is reduction of the hypertrophied left ventricular septum which obstructs blood flow. A surgical approach consists of an open-heart myomectomy, while the less invasive percutaneous approach involves creating a myocardial infarction by injecting 95 to 100% ethanol through a septal artery, a procedure termed alcohol septal ablation (ASA). Although less invasive than myomectomy, there are several limitations of alcohol septal ablation. The most important appears to be full thickness infarction that is often complicated by heart block and ventricular tachycardia/fibrillation. The ideal therapy for septal hypertrophy would be to find an agent that induces a less severe injury and/or atrophy of the hypertrophied septum. We review several alternative techniques for selective injury of the septum and describe the ideal characteristics of such an ideal agent. Our central hypothesis is that the anthracycline antibiotic such as doxorubicin may be the perfect agent. Anthracycline-based chemotherapies have been used in the treatment of solid and hematological tumors for many years. These agents have known cardiotoxic side effects that are related to cumulative dose which can lead to heart failure. Although the mechanism of action of doxorubicin cardiotoxicity is controversial, it is very clear that these agents cause atrophy of the myocardium, induce apoptosis and necrosis, as well as anti-angiogenic effects. We propose that selectively treating the hypertrophied septum of HCM patients with injection of the anthracycline doxorubicin will lead to superior outcomes compared to ASA.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version